Patents show all

4Applications

Clinical Trials show all

1Phase 11Phase 2

SEC Filings show all

8-K4810-Q1010-K3D1S-11

SEC Form D Funding Events

DateOfferedSoldType
2012-03-22$3,804,991$3,804,991Equity, Option to Acquire, Security to be Acquired

Key Executives

  • Michael Cohen
    Executive Officer, Director
  • Roger Fidler
    Director
  • Steven Byle
    Executive Officer, Director
  • Ian McNiece
    Executive Officer, Director